Goodwin Advised Agomab on Pricing of $200 Million Initial Public Offering

Goodwin Advised Agomab on Pricing of $200 Million Initial Public Offering

The Goodwin Life Sciences team advised Agomab Therapeutics NV (“Agomab”) on the pricing of its initial public offering of 12,500,000 American Depositary Shares (“ADSs”) representing 12,500,000 of its common shares, at a public offering price of $16.00 per ADS. The gross proceeds to Agomab from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $200.0 million. All of the ADSs are being offered by Agomab. In addition, Agomab has granted the underwriters a 30-day option to buy an additional 1,875,000 ADSs at the initial public offering price, less underwriting discounts and commissions.

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Agomab’s product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. Agomab’s mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.

The Goodwin team was led by Michael Bison (Partner), Marishka DeToy (Partner), Stephanie Richards (Partner), Kristen McCarthy (Associate), Claire Treesh (Associate), Kevin Boyle (Associate) and Steven Dilsizian (Associate).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.